Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with SARS corona virus spike protein
OwnerRalf Altmeyer, Beatrice Nal-Rogier +7inventors
InventorsRalf Altmeyer, Beatrice Nal-Rogier, Cheman Chan, Francois Kien, Yiu Kam, Yu Siu, Kong Tse, Isabelle Staropoli, Jean-Claude Manuguerra
Life of this patent
Estimating the term…
Abstract
Nucleic acid molecules, polypeptides, immunogenic compositions, vaccines, and methods of making and using the nucleotides and encoded polypeptides associated with the Spike protein of SARS Corona Virus (SARS CoV) are disclosed.
Claims57
A purified nucleic acid molecule comprising SEQ ID NO:
- 2 (Spike-Pasteur-modif), SEQ ID NO:
- 3 (Spike-HKU-PRC), or SEQ ID NO:
- 6.
A purified nucleic acid molecule encoding an amino acid sequence comprising the sequence of SEQ ID NO:
- 4 or SEQ ID NO:
- 7, wherein said purified nucleic acid molecule shows increased expression of Spike protein as compared to SEQ ID NO:
- 1.
A purified nucleic acid molecule that hybridizes to either strand of a denatured, double-stranded DNA comprising the nucleic acid sequence of SEQ ID NO:
- 3 or SEQ ID NO:
- 6 under conditions of high stringency.
A purified polypeptide comprising SEQ ID NO:
- 4, SEQ ID NO:
- 5, or SEQ ID NO:
- 7.
A method for improving the expression of SARS CoV Spike polypeptide by a nucleic acid molecule comprising reducing the number of negative cis-acting signals in the nucleic acid molecule, wherein the reduction in the number of negative cis-acting signals occurs without altering the sequence of said SARS CoV Spike polypeptide.
An isolated immunological complex comprising a SARS CoV Spike polypeptide and an antibody that specifically recognizes said polypeptide.
A method for detecting infection by SARS virus, wherein the method comprises providing a composition comprising a biological material suspected of being infected with SARS virus, and assaying for the presence of Spike polypeptide.
An in vitro diagnostic method for the detection of the presence or absence of antibodies, which bind to an antigen comprising SARS CoV Spike polypeptide, wherein the method comprises contacting the antigen with a biological fluid for a time and under conditions sufficient for the antigen and antibodies in the biological fluid to form an antigen-antibody complex, and detecting the formation of the complex.
A diagnostic kit for the detection of the presence or absence of antibodies, which bind to SARS CoV Spike polypeptide or mixtures thereof, wherein the kit comprises an antigen comprising SARS CoV Spike polypeptide or mixtures of SARS CoV Spike polypeptides, and means for detecting the formation of immune complex between the antigen and antibodies, wherein the means are present in an amount sufficient to perform said detection.
An immunogenic composition comprising at least one SARS CoV Spike polypeptide in an amount sufficient to induce an immunogenic or protecting response in vivo, and a pharmaceutically acceptable carrier therefor.
A method for detecting the presence or absence of SARS CoV comprising:
- (1) contacting a sample suspected of containing viral genetic material of SARS CoV with at least one nucleotide probe, and
- (2) detecting hybridization between the nucleotide probe and the viral genetic material in the sample, wherein said nucleotide probe is complementary to the full-length sequence of the purified nucleic acid of SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, or SEQ ID NO:
- 6.
A plasmid deposited at C.N.C.M having the accession number I-3221, I-3222, or I-3223.
A polynucleotide encoding a fragment of the SARS CoV Spike polypeptide having at least one mutation compared with SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, or SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.